| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S12482 R47051 |
Benevent, 2023 | Very preterm (< 32 weeks) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: SSRI only | 1.63 [1.04;2.54] C | 20/1,638 1,102/146,034 | 1,122 | 1,638 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18233 R76470 |
Rommel, 2022 | Very preterm (28–3 2 weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Monotherapy: SSRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.05 [0.82;1.34] | -/16,429 -/23,676 | - | 16,429 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5430 R21326 |
Norby, 2016 | Gestational age <32 at birth | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 0.80 [0.70;1.00] | -/17,736 -/718,533 | - | 17,736 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6107 R15967 |
Malm (Controls unexposed, disease free), 2015 | Preterm birth <32 weeks | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes Monotherapy: no or not specified |
0.78 [0.57;1.07] excluded (control group) |
80/15,729 186/31,394 | 266 | 15,729 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5374 R15951 |
Malm (Controls unexposed, sick), 2015 | Preterm birth <32 weeks | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.52 [0.37;0.74] | 80/15,729 93/9,652 | 173 | 15,729 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5379 R17687 |
Roca, 2011 | Early preterm birth (< 32 weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No Matched Monotherapy: no or not specified | 2.01 [0.04;101.99] C | 0/84 0/168 | 0 | 84 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5408 R16598 |
Wisner (Controls unexposed, disease free), 2009 | Early Preterm (<34 weeks) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Monotherapy: no or not specified |
5.65 [0.50;63.81] C excluded (control group) |
2/48 1/131 | 3 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6249 R16606 |
Wisner (Controls unexposed, sick), 2009 | Early Preterm (<34 weeks) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 0.57 [0.05;6.74] C | 2/48 1/14 | 3 | 48 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 0.90 [0.64;1.25] | 1,298 | 51,664 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = 0.8083 (by Egger's regression)
slope=-0.1998 (0.2391); intercept=0.3892 (1.5021); t=0.2591; p=0.8083
excluded 5408, 6107